Eyecyte-RPE™
Phase 2Small molecule
Eyecyte-RPE™ is one of 32 small molecule programs targeting Age-Related Macular Degeneration. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Tecfidera
BiogenApproved
Bayer Aspirin
BayerApproved
Zometa
PfizerApproved
Plavix
SanofiApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eyecyte-RPE™. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEyestem Research Pvt. Ltd.